Two of the largest drug makers – Amgen and Genentech – are both cutting numerous jobs in coming weeks, adding to a growing number of layoffs in the pharmaceutical industry this year.

Amgen plans to eliminate about 200 R&D positions, mostly in California, by the end of the year as the company makes “organizational changes” to its R&D apparatus, a spokeswoman confirmed. The cuts are being made at facilities in Thousand Oaks, Calif., and South San Francisco. The move comes eight months after Amgen reassigned about 100 R&D jobs from Thousand Oaks to South San Francisco and Cambridge, Mass.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy